Peijia Medical Limited (HKG:9996)
 5.75
 +0.04 (0.70%)
  Oct 31, 2025, 9:44 AM HKT
Peijia Medical Revenue
Peijia Medical had revenue of 353.38M CNY in the half year ending June 30, 2025, with 57.15% growth. This brings the company's revenue in the last twelve months to 667.66M, up 29.03% year-over-year. In the year 2024, Peijia Medical had annual revenue of 615.48M with 39.53% growth.
Revenue (ttm) 
 667.66M CNY
Revenue Growth 
 +29.03%
P/S Ratio 
 5.22
Revenue / Employee 
 637.69K CNY
Employees 
 1,047
Market Cap 
3.82B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 615.48M | 174.36M | 39.53% | 
| Dec 31, 2023 | 441.13M | 190.29M | 75.86% | 
| Dec 31, 2022 | 250.83M | 114.30M | 83.71% | 
| Dec 31, 2021 | 136.53M | 97.88M | 253.21% | 
| Dec 31, 2020 | 38.66M | 19.96M | 106.72% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| JD Health International | 71.34B | 
| BeOne Medicines AG | 35.81B | 
| Sino Biopharmaceutical | 33.49B | 
| Alibaba Health Information Technology | 32.81B | 
| CSPC Pharmaceutical Group | 28.49B | 
| WuXi Biologics | 21.98B | 
| Hansoh Pharmaceutical Group Company | 14.45B | 
| Innovent Biologics | 12.52B |